Published in Health Business Week, April 30th, 2004
The company had a net loss of $1,659,875 or $0.06 per share for the year ended December 31, 2003, compared with net loss of $1,404,547 or $0.05 per share for the year ended December 31, 2002.
The net loss for 2003 resulted primarily from the continued research and development expenditures related to the conduct of phase I clinical trials to study the company's product, Thymosin Beta 4 (TB4) for the treatment of chronic dermal wounds, and the administrative costs associated with managing the company's various projects.
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Health Business Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.